Mosaic Therapeutics appoints Dr Vince O’Neill, MD, as Head of R&D

This section is Partnership Content suppliedThe content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article content– Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team – Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipelineCAMBRIDGE, England — Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth.Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentArticle content“We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentsaid Thomas Fuchs, CEO, Mosaic Therapeutics.Article content“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.”Article contentVince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Development and Chief Medical Officer, having previously held roles including Chief R&D Officer at OnkosXcel Therapeutics, and CMO roles at MIRNA Therapeutics and Exosome Diagnostics. Additionally, he has held various senior clinical development and medical leadership positions at Sanofi-Aventis, GSK, Genentech and Roche, playing an instrumental role in the development and commercialisation of multiple high-impact oncology therapeutics, including Avastin, Venclexta, Tarceva, Merkinist, and Tafinlar. In early-stage biotech, he has also secured successful public ($420M) and private ($65M series B) financing raises as part of executive leadership teams. He obtained his BSc, MD and MBChB in Medicine from the University of Glasgow.Article contentVince O’Neill, Head of R&D, Mosaic Therapeutics, commented:Article content“Article contentI look forward to working closely with the Board and the team to advance our programs into the clinic and for the opportunity to develop novel combination therapies for cancer patients, utilising innovative biomarker strategies to maximise patient benefit.”Article contentAbout Mosaic TherapeuticsArticle contentMosaic Therapeutics is an oncology therapeutics company building the category leader in Synergistic Precision Oncology. The company’s mission is to tackle cancers with substantial unmet need and few targeted treatment options, by applying its advanced experimental and computational platform to identify oncology combinations that have synergistic activity in biomarker-defined patient populations.Article contentBorn out of pioneering research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute, Mosaic has active programs across a variety of oncology indications and disease biology pathways.Article contentThe Company’s pipeline is anchored by ASTX295, an MDM2 antagonist, and ASTX029, an ERK1/2 inhibitor, both in-licensed from Astex Pharmaceuticals in April 2025. Mosaic’s first clinical combination study is expected to commence in early 2027.Article contentLinkedIn: https://linkedin.com/company/mosaic-tx Website: https://mosaic-tx.com/Article contentArticle contentArticle contentView source version on businesswire.com: Article content https://www.businesswire.com/news/home/20260331713463/en/Article contentArticle contentContactsArticle contentTrending U.S. targets Canada’s cloud-computing move as trade irritant Economy Red Lobster to bring back endless shrimp deal that drove it to bankruptcy Retail & Marketing Suncor reveals expansion plans as key oilsands mine enters its last decade Energy U.S. within 'weeks' of oil shortages if war in Iran continues: Eric Nuttall Oil & Gas Terence Corcoran: Canada hates Trump but loves his economics FP Comment Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. U.S. targets Canada’s cloud-computing move as trade irritant Economy Red Lobster to bring back endless shrimp deal that drove it to bankruptcy Retail & Marketing Suncor reveals expansion plans as key oilsands mine enters its last decade Energy U.S. within 'weeks' of oil shortages if war in Iran continues: Eric Nuttall Oil & Gas Terence Corcoran: Canada hates Trump but loves his economics FP Comment